Neurocrine Biosciences
NBIX
150.57
-6.02
-3.84%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
150.57
-6.02
-3.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 102.30% -0.89pp
- Institutions
- 972 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund78.92%
Hedge Fund13.49%
Public Company3.46%
Government Pension Fund2.64%
Private Company1.64%
Individual/Insider1.20%
Sovereign Wealth Fund1.07%
Insurance Company0.33%
VC/PE Fund0.22%
Endowment Fund0.17%
Family Office/Trust0.18%
Top holders as of 2026-09-30
BlackRock
14.68% · 14.86M sh
Dodge & Cox
5.44% · 5.50M sh
Vanguard Capital Management, LLC
5.17% · 5.24M sh
Vanguard Portfolio Management, LLC
5.00% · 5.06M sh
J.P. Morgan Asset Management, Inc.
4.90% · 4.96M sh
State Street Global Advisors
4.75% · 4.81M sh
AQR Capital Management
2.99% · 3.03M sh
Vestal Point Capital, LP
2.47% · 2.50M sh
Renaissance Technologies Corp.
2.27% · 2.30M sh
Two Sigma Investments, LP
2.05% · 2.08M sh
Geode Capital Management, LLC
2.10% · 2.13M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 16 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Kevin Gorman | Director | 0.51% |
| Kyle Gano | Chief Executive Officer | 0.15% |
| Gary Lyons | Independent Director | 0.12% |
| Eric Benevich | Chief Commercial Officer | 0.07% |
| Darin Lippoldt | Chief Legal Officer | 0.06% |
| Eiry Roberts | Chief Medical Officer | 0.05% |
| William Rastetter | Independent Chairperson | 0.04% |
| Matthew Abernethy | Chief Financial Officer | 0.04% |
| Richard Pops | Independent Director | 0.04% |
| Julie Cooke | Chief Human Resources Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Sanjay Keswani | Former Chief Medical Officer | Intent to Sell (Form 144) | -53,614 | $167.37 |
| 2026-11-03 | Eiry Roberts | Chief Medical Officer | Other Derivative Acquisition | +1,506 | -- |
| 2026-11-03 | Eiry Roberts | Chief Medical Officer | Other Derivative Acquisition | +8,314 | $166.05 |
| 2026-11-02 | George Morrow | Independent Director | Derivative Exercise and Sale | -15,000 | $53.64–168.53 |
| 2026-10-31 | Kyle Gano | Chief Executive Officer | Derivative Exercise and Sale | -332 | $146.10 |
| 2026-10-31 | Kyle Gano | Chief Executive Officer | Derivative Exercise and Retained | +282 | -- |
| 2026-09-27 | Eiry Roberts | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-13 | Matthew Abernethy | Chief Financial Officer | Automatic Disposition | -2,311 | $157.20 |
| 2026-09-13 | David Boyer | Chief Corporate Affairs Officer | Automatic Disposition | -826 | $157.45 |
| 2026-09-10 | Kevin Gorman | Director | Sale to Issuer | -7,839 | $156.22 |
| 2026-09-10 | Kevin Gorman | Director | Other Acquisition | +14,343 | -- |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Sale to Issuer | -3,386 | $156.22 |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Other Acquisition | +6,275 | -- |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Sale to Issuer | -2,419 | $156.22 |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Other Acquisition | +4,483 | -- |
| 2026-09-10 | Kyle Gano | Chief Executive Officer | Sale to Issuer | -4,380 | $156.22 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Neurocrine Biosciences discussion 0 comments